SoftBank bets $1.1B on Roivant CEO Vivek Ramaswamy’s brash new biotech strategy
With pivotal data looming on his first big biotech play, Vivek Ramaswamy just landed a whopping $1.1 billion investment to back the explosive growth of Roivant Sciences. And he has a new fledgling ‘vant’ to add to the portfolio today — his 6th — as Roivant muscles up on data analysis tech.
SoftBank Vision Fund — a massive $100 billion private equity fund from Japan’s SoftBank with huge contributions from the Saudis and a slate of tech companies like Apple and Sharp — is contributing the cash, which includes funds from some of Roivant’s existing investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.